Clin Pediatr Hematol Oncol.  2019 Apr;26(1):12-26. 10.15264/cpho.2019.26.1.12.

Advances in the Treatment of Childhood Acute Lymphoblastic Leukemia

Affiliations
  • 1Division of Pediatric Hematology/Oncology, Department of Pediatrics, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea. taban@hanmail.net

Abstract

In recent decades, survival rates for childhood acute lymphoblastic leukemia have improved remarkably, as demonstrated by risk-stratified, prospective multicenter studies. Treatment protocols have evolved and become better matched to both prognostic factors and treatment responses. Recently, new molecular prognostic factors have been discovered in leukemia genomic studies. New tumor subtypes with independent gene expression profiles have also been characterized. Furthermore, therapies targeted to specific candidate mutations are being identified to broaden therapeutic options for patients with poor prognoses. Many new drugs are in clinical trials and immunotherapy is attracting significant interest for the treatment of recurrent or refractory disease in childhood acute lymphoblastic leukemia.

Keyword

Childhood; Precursor cell lymphoblastic leukemia; Prognosis; Survival

MeSH Terms

Clinical Protocols
Humans
Immunotherapy
Leukemia
Precursor Cell Lymphoblastic Leukemia-Lymphoma*
Prognosis
Prospective Studies
Survival Rate
Transcriptome
Full Text Links
  • CPHO
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
    DB Error: unknown error